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Background
The heme-containing nitric oxide (NO) receptor, sGC can
exist in the NO-sensitive reduced (Fe2+) state and NO-
insensitive oxidized (Fe3+)/heme free form. Indeed, the
redox state of sGC can be probed using the NO-independ-
ent sGC activator, BAY 58–2667, which preferentially tar-
gets sGC in its oxidized states. We hypothesised that in the
resistance vasculature, sGC exists in the Fe2+, Fe3+ and
heme-free forms and the ratio of these redox states is
altered under conditions of oxidative stress.
Materials and methods
Small mesenteric arteries (~300 μm diam) from male
Sprague Dawley rats were mounted in small vessel myo-
graphs and isometric force measured. Vessels were pre-
contracted (~50%) with U46619 and cumulative
concentration-response curves to sGC activators which
target sGC in its Fe2+ (DEA/NO), Fe3+ (BAY 58–2667) and
heme-free states (BAY 58–2667, PPIX) were examined.
Results
BAY 58–2667 was the most potent vasodilator studied
(pEC50 = 12.82 ± 0.13, -log M) with a maximal relaxation
of 91.9 ± 1.9% (n = 6). Its potency was increased up to
200-fold (P < 0.0001) upon oxidation of sGC by ODQ
(10 μM, n = 6) and in the presence of the NO synthase
inhibitor, L-NAME (100 μM, n = 4). Similarly, ODQ
enhanced vasorelaxation to PPIX yet impaired the
response to DEA/NO (control pEC50 = 7.24 ± 0.11 vs
ODQ pEC50 = 5.68 ± 0.08, n = 5–10, P < 0.0001). Zn-PPIX
(3&10 μM), an inhibitor of heme-free sGC, caused a con-
centration-dependent right-ward shift in the relaxation
response to BAY 58–2667 such that the potency was
decreased 30- (P = 0.0001, n = 6) and 3000-fold (P <
0.0001, n = 6), respectively. The response to PPIX (pEC50
= 5.31 ± 0.57, Rmax = 55.5 ± 5.8%) was abolished in the
presence of 3 μM Zn-PPIX (P < 0.0001) yet vasorelaxation
to DEA/NO was unchanged. The peroxynitrite donor,
SIN-1 (1 mM) decreased the sensitivity to DEA/NO 15-
fold (P = 0.0003, n = 4) yet the response to BAY 58–2667
was unaffected.
Conclusion
The vasodilator efficacy of BAY 58–2667 and PPIX in
small mesenteric arteries suggests that a relatively
enhanced pool of oxidized/heme-free sGC exists in the
resistance vasculature under physiological conditions and
this pool may be increased during oxidative stress and in
the absence of endogenous NO. This establishes sGC acti-
vation as a novel pharmacological approach for both dis-
ease- and region-specific vasodilator therapy.
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